Cargando…

Equine seroprevalence of West Nile virus antibodies in the UK in 2019

BACKGROUND: West Nile virus (WNV) is a single-stranded RNA virus that can cause neurological disease in both humans and horses. Due to the movement of competent vectors and viraemic hosts, WNV has repeatedly emerged globally and more recently in western Europe. Within the UK, WNV is a notifiable dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Folly, Arran J., Waller, Elisabeth S. L., McCracken, Fiona, McElhinney, Lorraine M., Roberts, Helen, Johnson, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690108/
https://www.ncbi.nlm.nih.gov/pubmed/33243297
http://dx.doi.org/10.1186/s13071-020-04481-9
_version_ 1783614001340481536
author Folly, Arran J.
Waller, Elisabeth S. L.
McCracken, Fiona
McElhinney, Lorraine M.
Roberts, Helen
Johnson, Nicholas
author_facet Folly, Arran J.
Waller, Elisabeth S. L.
McCracken, Fiona
McElhinney, Lorraine M.
Roberts, Helen
Johnson, Nicholas
author_sort Folly, Arran J.
collection PubMed
description BACKGROUND: West Nile virus (WNV) is a single-stranded RNA virus that can cause neurological disease in both humans and horses. Due to the movement of competent vectors and viraemic hosts, WNV has repeatedly emerged globally and more recently in western Europe. Within the UK, WNV is a notifiable disease in horses, and vaccines against the virus are commercially available. However, there has been no investigation into the seroprevalence of WNV in the UK equine population to determine the extent of vaccination or to provide evidence of recent infection. METHODS: Equine serum samples were obtained from the Animal and Plant Health Agency’s equine testing service between August and November 2019. A total of 988 serum samples were selected for horses resident in South East England. WNV seroprevalence was determined using two enzyme-linked immunosorbent assays (ELISAs) to detect total flavivirus antibodies and WNV-specific immunoglobulin M (IgM) antibodies. Positive IgM results were investigated by contacting the submitting veterinarian to establish the clinical history or evidence of prior vaccination of the horses in question. RESULTS: Within the cohort, 274 samples tested positive for flavivirus antibodies, of which two subsequently tested positive for WNV-specific IgM antibodies. The follow-up investigation established that both horses had been vaccinated prior to serum samples being drawn, which resulted in an IgM-positive response. All the samples that tested positive by competition ELISA were from horses set to be exported to countries where WNV is endemic. Consequently, the positive results were likely due to previous vaccination. In contrast, 714 samples were seronegative, indicating that the majority of the UK equine population may be susceptible to WNV infection. CONCLUSIONS: There was no evidence for cryptic WNV infection in a cohort of horses sampled in England in 2019. All IgM-seropositive cases were due to vaccination; this should be noted for future epidemiological surveys in the event of a disease outbreak, as it is not possible to distinguish vaccinated from infected horses without knowledge of their clinical histories. [Image: see text]
format Online
Article
Text
id pubmed-7690108
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-76901082020-11-30 Equine seroprevalence of West Nile virus antibodies in the UK in 2019 Folly, Arran J. Waller, Elisabeth S. L. McCracken, Fiona McElhinney, Lorraine M. Roberts, Helen Johnson, Nicholas Parasit Vectors Short Report BACKGROUND: West Nile virus (WNV) is a single-stranded RNA virus that can cause neurological disease in both humans and horses. Due to the movement of competent vectors and viraemic hosts, WNV has repeatedly emerged globally and more recently in western Europe. Within the UK, WNV is a notifiable disease in horses, and vaccines against the virus are commercially available. However, there has been no investigation into the seroprevalence of WNV in the UK equine population to determine the extent of vaccination or to provide evidence of recent infection. METHODS: Equine serum samples were obtained from the Animal and Plant Health Agency’s equine testing service between August and November 2019. A total of 988 serum samples were selected for horses resident in South East England. WNV seroprevalence was determined using two enzyme-linked immunosorbent assays (ELISAs) to detect total flavivirus antibodies and WNV-specific immunoglobulin M (IgM) antibodies. Positive IgM results were investigated by contacting the submitting veterinarian to establish the clinical history or evidence of prior vaccination of the horses in question. RESULTS: Within the cohort, 274 samples tested positive for flavivirus antibodies, of which two subsequently tested positive for WNV-specific IgM antibodies. The follow-up investigation established that both horses had been vaccinated prior to serum samples being drawn, which resulted in an IgM-positive response. All the samples that tested positive by competition ELISA were from horses set to be exported to countries where WNV is endemic. Consequently, the positive results were likely due to previous vaccination. In contrast, 714 samples were seronegative, indicating that the majority of the UK equine population may be susceptible to WNV infection. CONCLUSIONS: There was no evidence for cryptic WNV infection in a cohort of horses sampled in England in 2019. All IgM-seropositive cases were due to vaccination; this should be noted for future epidemiological surveys in the event of a disease outbreak, as it is not possible to distinguish vaccinated from infected horses without knowledge of their clinical histories. [Image: see text] BioMed Central 2020-11-26 /pmc/articles/PMC7690108/ /pubmed/33243297 http://dx.doi.org/10.1186/s13071-020-04481-9 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Short Report
Folly, Arran J.
Waller, Elisabeth S. L.
McCracken, Fiona
McElhinney, Lorraine M.
Roberts, Helen
Johnson, Nicholas
Equine seroprevalence of West Nile virus antibodies in the UK in 2019
title Equine seroprevalence of West Nile virus antibodies in the UK in 2019
title_full Equine seroprevalence of West Nile virus antibodies in the UK in 2019
title_fullStr Equine seroprevalence of West Nile virus antibodies in the UK in 2019
title_full_unstemmed Equine seroprevalence of West Nile virus antibodies in the UK in 2019
title_short Equine seroprevalence of West Nile virus antibodies in the UK in 2019
title_sort equine seroprevalence of west nile virus antibodies in the uk in 2019
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690108/
https://www.ncbi.nlm.nih.gov/pubmed/33243297
http://dx.doi.org/10.1186/s13071-020-04481-9
work_keys_str_mv AT follyarranj equineseroprevalenceofwestnilevirusantibodiesintheukin2019
AT wallerelisabethsl equineseroprevalenceofwestnilevirusantibodiesintheukin2019
AT mccrackenfiona equineseroprevalenceofwestnilevirusantibodiesintheukin2019
AT mcelhinneylorrainem equineseroprevalenceofwestnilevirusantibodiesintheukin2019
AT robertshelen equineseroprevalenceofwestnilevirusantibodiesintheukin2019
AT johnsonnicholas equineseroprevalenceofwestnilevirusantibodiesintheukin2019